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Amelioration of Carcinogen-Induced Toxicity in Mice by
Administration of a Potentized Homeopathic Drug, Natrum
Sulphuricum 200
Nandini Bhattacharjee, Surajit Pathak and Anisur Rahman Khuda-Bukhsh
Cytogenetics and Molecular Biology Laboratory, Department of Zoology, University of Kalyani, Kalyani-741235,
India
To examine if a potentized homeopathic drug, Natrum Sulphuricum 200 (Nat Sulph-200) has
protective potentials against hepatocarcinogenesis, liver tumors were induced in mice through
chronic feeding of P-dimethylaminoazobenzene (p-DAB; initiator of hepatocarcinogenesis) and
phenobarbital (PB; promoter). Mice were divided into five sub-groups: fed normal low protein
diet (Gr. I, normal control); fed normal low protein plus alcohol-200 (vehicle of the
homeopathic remedy) (Gr. II); fed diet mixed with 0.06% p-DAB plus 0.05% PB (Gr. III); fed
diet and carcinogens like Gr.III, plus alcohol 200 (positive control for drug fed mice) (Gr. IV)
and fed diet and carcinogens like Gr. III, plus Natrum Sulphuiricum-200 (Gr. V; drug fed).
Mice were sacrificed at day 7, 15, 30, 60, 90 and day 120 for study of cytogenetical endpoints
like chromosome aberrations (CA), micronuclei (MN), mitotic index (MI) and sperm head
anomaly (SHA) and biochemical toxicity parameters like aspartate amino transferase (AST),
alanine amino transferase (ALT), acid (AcP) and alkaline (AlkP) phosphatases, lipid
peroxidation (LPO) and reduced glutathione (GSH) content. Less number of liver tumors
were observed in Gr. V (drug fed) mice. Administration of Nat Sulph 200 reduced genomic
damage, activities of AcP, AlkP, AST, ALT, LPO and increased GSH content. Therefore,
independent replication of the study by others is encouraged.
Keywords: anti-carcinogenesis – azo dye induced liver cancer – geno- and cyto-toxicity
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Introduction
Complementary and alternative medicine (CAM) is one
of the growing areas in health care today (1–4),
particularly as supportive medicine in treating difficult
to cure diseases like cancer (5–7). Homeopathy is
becoming one of the popular alternative modes of
treatment (8–10). Because of ultra high dilutions of
most potentized homeopathic drugs, their efficacy in
treating diseases is often put to question. However, our
recent works which showed the efficacy of certain
homeopathic drugs in ameliorating p-dimethylaminoazo-
benzene (p-DAB) induced cancer in mice (11–14) have
aroused interest in testing other homeopathic drugs for
their possible anti-cancer effects. The azo dye p-DAB,
used occasionally as a food additive, is known to act as
initiator of liver cancer when used chronically (15–19)
and is known to cause hazard to humans and animals
(20–21). Phenobarbital (PB), predominantly used as an
anti-epileptic/sedative drug, is known to have carcino-
genic effect (22) to humans, mice and rats when
administrated repeatedly (23–26). The effects are more
pronounced when PB is used in combination with the
azo-dye, which unfailingly produce liver tumors that
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properly cited.ultimately become neoplastic (14,15,27). Therefore this
induced liver carcinoma serves as a good model for the
study of events during carcinogenesis as well as to test
if a drug has any anti-cancerous effect. Further,
homeopathic mode of treatment does not have any
known side effects and is less expensive than that of
conventional treatments of liver cancer which often needs
surgery and costly medicines in management.
Remedy Selection: Indication from a Pilot Study
We have for some time been screening some homeopathic
remedies, which are claimed to have pronounced effects
in protecting liver from toxicity or that are known to help
in recovery of liver dysfunction (e.g. Chelidonium,
Lycopodium, etc.), for their possible anti-hepatotoxic/
anti-tumorigenic effects since the primary target organ of
the carcinogens is the liver.
Potentized form of Natrum Sulphuricum is one such
remedy generally used by homeopathic practitioners for
various liver disorders having agreeable symptoms (28).
As chronic feeding of P-DAB and PB is known to cause
symptoms arising out of liver disorders and Natrum
Sulph being one of the remedies used to alleviate and
protect liver from toxic effects, we first conducted a pilot
study on the efficacy of Nat Sulph-30 with a limited
number of protocols (data unpublished). On getting a
positive result the present investigation was undertaken
with a primary objective of evaluating efficacy of Nat
Sulph-200 (a more diluted higher potency claimed to have
stronger and longer lasting effect) in amelioration of
carcinogen induced toxicity in mice utilizing several
widely accepted protocols of cytogenetical and biochem-
ical studies.
Implications In Brief of the Parameters Used
The parameters used in this study are important
genotoxicity and cyto-toxicity (particularly hepatotoxin)
biomarkers, either directly or indirectly implicated in the
development of liver tumors. The changes observed in the
cytogenetical studies led to the studies of LPO, which is
associated with tissue damage and necrosis. Similarly,
tissue damage and necrosis can lead to improper liver
function and thereby causing hepato-toxicity. For this,
liver function tests, that include the assay of various
enzymes like AcP, AlkP, AST and ALT were selected to
throw light on the extent of liver malfunctioning, if any.
Further, if hepato-toxicity is generated, there will be
generation of free radicals. GSH has anti-oxidant activity
which is accomplished by scavenging free-radicals and the
study of GSH was therefore of added value. Further,
while decrease of the other biochemical parameters
indicates decreased hepato-toxicity, a concomitant
increase in GSH is expected to confirm this.
Methods
Feeding the Carcinogens and the Homeopathic Remedy to
Mice
An inbred strain of Swiss albino mice (Mus musculus)
were reared and maintained in the animal house of the
Department of Zoology (with clearance from the
University Ethical Committee and under the supervision
of the Animal Welfare Committee), University of
Kalyani, India, for the investigation. Mice under experi-
ment were provided food and water and kept in a
hygienic condition. The general diet was prepared
from wheat, gram and powdered milk without any
animal protein supplement. A group of 36 healthy
mice weighing between 25–30g were used for
each treatment series, namely, (i) normal, (ii) normalþ
alcohol 200 (iii) P-dimethylaminoazobenzene (p-DAB)þ
phenobarbital (PB), (iv) p-DABþPBþalcohol 200,
(v) p-DABþPBþNat Sulph-200 fed series. In our earlier
studies, we used to maintain another group, only verum
fed control along with normalþsuccussed alcohol fed
control. But since the differences in data between these
two series were negligible or insignificant, the normalþ
verum fed group as control was later abandoned for
saving life of mice and cost.
Each group of 36 mice divided into six different sets
consisting of six mice each for six different intervals of
fixation, namely, at day seven, 15, 30, 60, 90 and 120.
The first set of mice (group-I, normal, negative control)
was fed normal low protein diet. The second set of mice
(group II) was fed diluted alcohol 200 (potentized as per
homeopathic principle of dilution and succussion) with
normal low protein diet. The third set of mice (group-III)
was fed the same diet but mixed with 0.06% p-DAB
(Sigma, D-6760) at a daily dose of 165mg/kg body wt.
per mouse (15,27,29) and an oral dose of 0.06ml of
0.05% aqueous solution of PB daily (14,30) through a
specially made fine pipette. The fourth set of mice
(group-IV, positive control) was fed 0.06% p-DAB along
with 0.05% aqueous solution of PB as above and
also diluted alcohol 200 (alc-200: as the ‘vehicle’ of the
drug was ethyl alcohol), till they were sacrificed. The
fifth set of mice (group-V) was fed p-DAB plus PB as
in group-III, but was also fed Nat Sulph-200 once a
day till they were sacrificed at day seven, 15, 30, 60, 90
and 120.
Feeding Procedure and Dose
Each mouse was fed one drop (0.06ml) of stock
solution of Nat Sulph-200 or alc-200, as the case
may be, once daily (one dose at 7A.M) with the aid of
a fine pipette.
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The potentized homeopathic drug, Nat Sulph-200, was
procured from ‘HAPCO’, 165, Bipin Behari Ganguly
Street, Kolkata, India. The 200 potency of Natrum Sulph
was derived from the mother tincture of sodium sulphate
by ‘succussion and dilution’ procedure (31,32) as
recommended in the Homeopathic Pharmacopoeia of
India, Vol. I (33). The glass vial containing potentized
alc-200 provided by ‘HAPCO’ having been accidentally
broken during the initial days of experiment, the
available ‘placebo’ provided by Boiron Lab, Lyon,
France, had been used. However, we examined various
physical properties of both the ‘placebos’ prepared by
‘HAPCO’ and ‘BOIRON’ through UV, FTIR, fluores-
cence, 13 C-NMR and 1H-NMR spectroscopy earlier
(34) but failed to observe any significant difference
between the two ‘placebos’.
Laboratory Methodology
Cytogenetic Assay
The standard and widely practiced cytogenetic protocols
like assays of chromosome aberration (CA), micronuclei
(MN), mitotic index (MI) and sperm head anomaly
(SHA) have been adopted in the present study for testing
genotoxicity (14,26). A total of 300 bone marrow cells
were observed for CA, 3000 cells for MN and 5000 cells
for MI and 5000 sperm for SHA analysis.
Biochemical Assays
After collection of blood by ventricular puncture from
etherized mice (approx 1.5ml from each mouse), they
were sacrificed and their liver and spleen were quickly
collected in an ice tray.
For the study of aspartate and alanine amino trans-
ferases (AST and ALT, respectively), acid and alkaline
phosphatases (AcP and AlkP, respectively) and lipid
peroxidation (LPO) and reduced glutathione content
(GSH) standard methods (14) were adopted.
Statistical Analysis
The significance of difference between data of the
different series was conducted by Student’s t-test and
two-way ANOVA (Mini Tab 13.01) was performed. This
experiment was done as per randomized double blind
placebo control method.
Results
Tumor Growth
Out of 18 mice sacrificed at three longer fixation intervals
(i.e. at day 60, 90 and 120), 15 and 16 mice, respectively,
showed liver tumors in the p-DABþPB fed and
p-DABþPBþalc-200 fed series, while altogether eight
mice showed liver tumors in the drug fed series (Table 1).
The tumors looked pale reddish in color. Some of them
were present as solitary or a few individually distinguish-
able ones (mostly in drug fed mice) much less in
magnitude than the multiple innumerable nodules
(mostly in drug unfed mice), which were considered as
true tumors and the one or two nodules present in a few
were ignored. On this estimate, Nat Sulph-200 fed mice
showed an overall protection to the tune of 41.7%
(Nat Sulph-30 rendered 31.1%, unpublished data) when
data of all three longer intervals of fixation were
considered.
Cytogenetical Studies
As compared with normal metaphase plate (Fig.1A),
there was a palpable increase in the frequencies of
various types of CA (Fig. 1B–D) in different treatment
series during all fixation periods. Several types of
chromosome aberrations — both of major and minor
types — were observed in certain metaphase plates of
p-DABþPB and p-DABþPBþalc-200 fed mice. The
total frequencies of aberrations were maximum in
p-DABþPBþalc-200 fed mice. The frequency of CA
was always greater in p-DABþPB fed mice than in
normal (Gr. I) and normalþalc-200 fed (Gr. II) mice.
Table 1. Number of animals showing tumors at different fixation intervals after chronic feeding of p-DAB plus PB for 7, 15, 30, 60, 90 and 120 days,
in each fixation intervals 6 mice each were used per set
Series No. of
specimens
used
Tumor
incidence
7 days
Tumor
incidence
15 days
Tumor
incidence
30 days
Tumor
incidence
60 days
Tumor
incidence
90 days
Tumor
incidence
120 days
Normal 36 0/6 0/6 0/6 0/6 0/6 0/6
NormalþAlc-200 36 0/6 0/6 0/6 0/6 0/6 0/6
p-DABþPB 36 0/6 0/6 0/6 3/6 6/6 6/6
p-DABþPBþAlc-200 36 0/6 0/6 0/6 4/6 6/6 6/6
p-DABþPBþNat Sulph-200 36 0/6 0/6 0/6 2/6 3/6 3/6
TOTAL 180 0/30 0/30 0/30 9/30 15/30 15/30
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fed group was found to be considerably decreased
(P50.01–P50.001) at all fixation intervals except at
day seven (Fig. 2A).
Micronucleated Erythrocytes
The incidence of micronuclei (Fig. 1E; which represent a
fragment or broken part or whole arm of a chromo-
some), in carcinogen fed as also p-DABþPBþalc-200
fed mice was appreciably higher than that of normal
control mice at all fixation intervals. However, there was
a palpable decrease in MN in the drug fed series
(P50.05–P50.001). The decrease was a result of
reduction in number of both polychromatic (PCE) and
normochromatic (NCE) erythrocytes (Fig. 2B).
Mitotic Index
The mitotic indices represent the rate at which the cells
pass through a cell cycle. When a cell becomes
transformed into a tumor cell, the rate becomes increased
for failure of proper control of cell division and thus
may be used as an indicator of tumorigenicity.
The mitotic indices of mice fed either p-DABþPB
or p-DABþPBþAlc-200 were higher than that of
the normal control series. In p-DABþPBþNat
Sulph-200 fed mice, there was a significant decrease
(P50.05–P50.001) in MI at all fixation intervals except
at day seven (Fig. 2C).
Sperm Head Anomaly
Genotoxic or carcinogenic or spermatotoxic agents can
cause damage to sperm head, which may be an indicator
of the risk of transmission of mutagenic trait, if these
deformed sperm by chance fertilize the ovum. Greater
number of sperm with abnormal head morphologies
(Fig. 1G) was encountered in p-DABþPB fed and
p-DABþPBþalc-200 fed mice at all fixation intervals.
The frequencies of SHA were considerably decreased in
p-DABþPBþNat Sulph-200 fed group at all fixation
intervals (P50.05–P50.001) (Fig. 2D) except at day 7.
Biochemical Assay
Aspartate Amino Transferase Activity (AST)
The AST activity in liver was increased in both
p-DABþPB fed and p-DABþPBþAlc-200 fed mice at
all fixation intervals. However, the AST activity in
p-DABþPBþNat Sulph-200 fed series appeared to
decrease significantly (P50.01–P50.001) from day
15 – day 120 (Table 2) in liver.
Alanine Amino Transferase Activity (ALT)
Similar trend of reduction in ALT activity (P50.01–
P50.001) was noticed in liver of the p-DabþPBþNat
Sulph-200 fed mice when compared to that of
p-DabþPBþAlc-200 fed mice at all fixation intervals
except at day seven (Table 3).
Acid Phosphatase Activity (AcP)
The activity of AcP in liver showed a trend of steady rise
from day 7 to day 15 in p-DabþPB fed mice, then
decreased at day 60 and 90, only to rise again at day 120.
The same trend was noticed in the p-DabþPBþAlc-200
fed series. The activity of AcP was decreased significantly
(P50.01) (Table 4) in the drug fed mice at all fixation
intervals except at day 7.
Alkaline Phosphatase Activity (AlkP)
The activity of AlkP was enhanced in liver of p-DabþPB
fed mice from day seven through day 120 and the same in
p-DabþPBþNat Sulph-200 fed mice decreased appreci-
ably (P50.05 through P50.001) at all fixation intervals
(Table 5).
Lipid Peroxidation (LPO)
Lipid peroxidation was considerably higher in p-Dabþ
PBþAlc-200 fed mice. However, there was a significant
Figure 1. (A–F). (A) Photomicrographs of normal metaphase comple-
ment, (B): Ring (R) and Centric fusion (CF), (C): Polyploidy,
(D): Terminal association (TA), (E): Erythrocyte showing micronucleus;
(F): Sperm with abnormal head shape.
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tion in liver of p-DabþPBþNat Sulph-200 fed mice at
all fixation intervals (Table 6).
Reduced Glutathione Content (GSH)
The reduced glutathione content decreased in p-Dabþ
PBþAlc-200 fed mice at all fixation intervals. However,
there was an increase in reduced glutathione content of
p-DabþPBþNat Sulph-200 fed mice at all fixation
intervals (P50.05 to P50.01) (Table 7) in liver.
Results of Statistical Analysis
The significance of differences between data of the
different series was determined by Student’s t-test and
the results of two-way ANOVA (Mini Tab 13.01) are
summarized in Tables 2–7 and Table 8–9.
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Figure 2. (A–D). Histograms showing the following: (A) percentage (%) of chromosomal aberrations (CA) in different series of mice at different
fixation intervals; (B) percentage (%) of micronucleated erythrocytes (MN) in different series of mice at different fixation intervals; (C) percentage
(%) of mitotic indices in different series of mice at different fixation intervals; and (D) percentage (%) of sperm head anomalies (SHA) in different
series of mice at different fixation intervals. Statistical analyses were done between series p-DABþPBþAlcohol-200 versus p-DABþPBþNat
Sulph-200. The different levels of statistical significances between two given series have been designated by *P50.05, **P50.01, ***P50.001.
p-DAB, p-dimethylaminoazobenzene; PB, phenobarbital; Nat Sulph-200, Natrum Sulphuricum-200.
eCAM 2009;6(1) 69Table 2. Mean Aspartate amino transferase (AST) activity in (nM/ 100mg protein/ Min) in liver of mice treated with p-DABþPB,
p-DABþPBþalc-200, p-DABþPBþNat Sulph-200, normal and negative controls at different fixation intervals. The different levels of
statistical significances between two given series have been designated by *, **, ***
Fixation intervals in days 7 days 15 days 30 days
Series AST activity SE AST activity SE AST activity SE
Liver Difference in activity Liver Difference in activity Liver Difference in activity
Normal 0.017 0.002 0.012 0.001 0.021 0.001
NormalþAlcohol 0.026 0.001 0.011 0.001 0.020 0.000
p-DABþPB 0.040 0.002 0.041 0.005 0.049 0.002
p-DABþPBþAlcohol 0.043 0.003 0.045 0.001 0.054 0.002
p-DABþPBþNat 0.050 0.003  0.007
n 0.040 0.001 0.005** 0.036 0.001 0.018***
Sulph-200
60 days 90 days 120 days
AST activity SE AST activity SE AST activity SE
Normal 0.024 0.004 0.010 0.001 0.054 0.002
NormalþAlcohol 0.021 0.002 0.012 0.004 0.056 0.004
p-DABþPB 0.047 0.006 0.056 0.004 0.075 0.007
p-DABþPBþAlcohol 0.053 0.002 0.059 0.001 0.107 0.012
p-DABþPBþNat 0.032 0.004 0.021** 0.041 0.002 0.018*** 0.046 0.002 0.061***
Sulph-200
*P50.05, **P50.01,***P50.001, n¼non-significant.
Statistical analyses were done between series p-DABþPBþAlcohol versus p-DABþPBþNat Sulph-200.
p-DAB, p-dimethylaminoazobenzene; PB, phenobarbital; Nat Sulph-200, Natrum Sulphuricum-200; SE, standard error.
Table 3. Mean Alanine amino transferase (ALT) activity in (nM/ 100mg protein/ Min) in liver of mice treated with p-DABþPB, p-DABþPBþ
alc-200, p-DABþPBþNat Sulph-200, normal and negative controls at different fixation intervals. The different levels of statistical significances
between two given series have been designated by *, **, ***
Fixation intervals in days 7 days 15 days 30 days
Series ALT activity SE ALT activity SE ALT activity SE
Liver Difference in activity Liver Difference in activity Liver Difference in activity
Normal 0.006 0.000 0.010 0.001 0.005 0.000
NormalþAlcohol 0.011 0.001 0.012 0.001 0.009 0.001
p-DABþPB 0.009 0.002 0.028 0.002 0.017 0.002
p-DABþPBþAlcohol 0.014 0.001 0.036 0.002 0.022 0.001
p-DABþPBþNat 0.021 0.001  0.007
n 0.026 0.001 0.010** 0.014 0.002 0.008**
Sulph-200
60 days 90 days 120 days
ALT activity SE ALT activity SE ALT activity SE
Normal 0.006 0.000 0.006 0.001 0.004 0.000
NormalþAlcohol 0.007 0.001 0.006 0.001 0.005 0.001
p-DABþPB 0.015 0.001 0.015 0.002 0.019 0.001
p-DABþPBþAlcohol 0.024 0.001 0.017 0.002 0.020 0.002
p-DABþPBþNat 0.011 0.003 0.013** 0.004 0.000 0.013*** 0.011 0.001 0.009**
Sulph-200
*P50.05, **P50.01, ***P50.001, n¼non-significant.
Statistical analyses were done between series p-DABþPBþAlcohol versus p-DABþPBþNat Sulph-200.
p-DAB, p-dimethylaminoazobenzene; PB, phenobarbital; Nat Sulph-200, Natrum Sulphuricum-200; SE, standard error.
70 Anti-carcinogenic potential of homeopathic remedyTable 4. Mean Acid phosphatase (AcP) activity in (nM/ 100mg protein/ Min) in liver of mice treated with p-DABþPB, p-DABþPBþalc-200,
p-DABþPBþNat Sulph-200, normal and negative controls at different fixation intervals. The different levels of statistical significances between two
given series have been designated by *, **, ***
Fixation intervals in days 7 days 15 days 30 days
Series AcP activity SE AcP activity SE AcP activity   SE
Liver Difference in activity Liver Difference in activity Liver Difference in activity
Normal 0.048 0.001 0.143 0.007 0.040 0.002
NormalþAlcohol 0.044 0.001 0.128 0.003 0.036 0.002
p-DABþPB 0.080 0.006 0.157 0.010 0.086 0.005
p-DABþPBþAlcohol 0.086 0.005 0.153 0.002 0.089 0.003
p-DABþPBþNat 0.087 0.003  0.001
n 0.137 0.004 0.016** 0.074 0.002 0.015**
Sulph-200
60 days 90 days 120 days
AcP activity SE AcP activity SE AcP activity SE
Normal 0.046 0.005 0.012 0.000 0.025 0.002
NormalþAlcohol 0.045 0.004 0.021 0.002 0.032 0.005
p-DABþPB 0.076 0.009 0.053 0.005 0.128 0.013
p-DABþPBþAlcohol 0.083 0.005 0.055 0.001 0.131 0.010
p-DABþPBþNat 0.052 0.006 0.031** 0.043 0.003 0.012** 0.087 0.003 0.044**
Sulph-200
*P50.05, **P50.01, ***P50.001, n¼non-significant.
Statistical analyses were done between series p-DABþPBþAlcohol versus p-DABþPBþNat Sulph-200.
p-DAB, p-dimethylaminoazobenzene; PB, phenobarbital; Nat Sulph-200, Natrum Sulphuricum-200; SE, standard error.
Table 5. Mean Alkaline phosphatase (AlkP) activity in (nM/ 100mg protein/ Min) in liver of mice treated with p-DABþPB, p-DABþPBþ
alc-200, p-DABþPBþNat Sulph-200, normal and negative controls at different fixation intervals. The different levels of statistical significances
between two given series have been designated by *, **, ***
Fixation intervals in days 7 days 15 days 30 days
Series AlkP activity SE AlkP activity SE AlkP activity SE
Liver Difference in activity Liver Difference in activity Liver Difference in activity
Normal 0.017 0.001 0.014 0.003 0.024 0.001
NormalþAlcohol 0.026 0.001 0.016 0.005 0.027 0.003
p-DABþPB 0.038 0.001 0.026 0.004 0.044 0.002
p-DABþPBþAlcohol 0.044 0.002 0.030 0.001 0.050 0.006
p-DABþPBþNat 0.049 0.008  0.005
n 0.022 0.003 0.008* 0.036 0.001 0.014*
Sulph-200
60 days 90 days 120 days
AlkP activity SE AlkP activity (activity SE) AlkP activity SE
Normal 0.021 0.001 0.019 0.001 0.012 0.001
NormalþAlcohol 0.023 0.001 0.026 0.001 0.033 0.005
p-DABþPB 0.034 0.001 0.045 0.004 0.139 0.006
p-DABþPBþAlcohol 0.038 0.001 0.048 0.004 0.150 0.003
p-DABþPBþNat 0.028 0.002 0.010** 0.032 0.001 0.016* 0.115 0.004 0.035***
Sulph-200
*P50.05, **P50.01, ***P50.001, n¼non-significant.
Statistical analyses were done between series p-DABþPBþAlcohol versus p-DABþPBþNat Sulph-200.
p-DAB, p-dimethylaminoazobenzene; PB, phenobarbital; Nat Sulph-200, Natrum Sulphuricum-200; SE, standard error.
eCAM 2009;6(1) 71Table 6. Mean Lipid peroxidation (LPO) activity in (nM/ MDA/ mg wet tissue) in liver of mice treated with p-DABþPB, p-DABþPBþ
alc-200, p-DABþPBþNat Sulph-200, normal and negative controls at different fixation intervals. The different levels of statistical significances
between two given series have been designated by *, **, ***
Fixation intervals in days 7 days 15 days 30 days
Series LPO activity SE LPO activity SE LPO activity SE
Liver Difference in activity Liver Difference in activity Liver Difference in activity
Normal 0.245 0.008 0.135 0.010 0.086 0.002
NormalþAlcohol 0.272 0.013 0.172 0.005 0.094 0.003
p-DABþPB 0.332 0.010 0.312 0.010 0.234 0.008
p-DABþPBþAlcohol 0.355 0.010 0.349 0.037 0.270 0.009
p-DABþPBþNat 0.417 0.011  0.062
n 0.192 0.002 0.157** 0.219 0.014 0.051*
Sulph-200
60 days 90 days 120 days
LPO activity SE LPO activity SE LPO activity SE
Normal 0.052 0.004 0.043 0.001 0.048 0.001
NormalþAlcohol 0.054 0.006 0.070 0.008 0.074 0.004
p-DABþPB 0.247 0.012 0.119 0.010 0.131 0.009
p-DABþPBþAlcohol 0.254 0.010 0.124 0.003 0.149 0.006
p-DABþPBþNat 0.141 0.009 0.113*** 0.090 0.004 0.034*** 0.118 0.004 0.03 1**
Sulph-200
*P50.05, **P50.01, ***P50.001, n¼non-significant.
Statistical analyses were done between series p-DABþPBþAlcohol versus p-DABþPBþNat Sulph-200.
p-DAB, p-dimethylaminoazobenzene; PB, phenobarbital; Nat Sulph-200, Natrum Sulphuricum-200; SE, standard error.
Table 7. Mean Reduced glutathione (GSH) content in (nM/ mg wet tissue) in liver of mice treated with p-DABþPB, p-DABþPBþalc-200,
p-DABþPBþNat Sulph-200, normal and negative controls at different fixation intervals. The different levels of statistical significances between
two given series have been designated by *, **, ***
Fixation intervals in days 7 days 15 days 30 days
Series GSH content SE GSH content SE GSH content SE
Liver Difference in activity Liver Difference in activity Liver Difference in activity
Normal 0.004 0.000 0.006 0.000 0.005 0.001
NormalþAl cohol 0.004 0.001 0.006 0.000 0.004 0.001
p-DABþPB 0.001 0.000 0.001 0.000 0.001 0.000
p-DABþPBþAlcohol 0.001 0.000 0.001 0.000 0.001 0.000
p-DABþPBþNat 0.001 0.000 0.000 0.003 0.000 0.002 0.004 0.001 0.003*
Sulph-200
60 days 90 days 120 days
GSH content SE GSH content SE GSH content SE
Normal 0.005 0.000 0.006 0.000 0.007 0.000
NormalþAlcohol 0.006 0.001 0.005 0.000 0.006 0.001
p-DABþPB 0.001 0.000 0.002 0.000 0.003 0.000
p-DABþPBþAlcohol 0.001 0.000 0.003 0.000 0.003 0.001
p-DABþPBþNat 0.005 0.001 0.004** 0.006 0.001 0.003* 0.006 0.000 0.003*
Sulph-200
*P50.05, **P50.01, ***P50.001, n¼non-significant.
Statistical analyses were done between series p-DABþPBþAlcohol versus p-DABþPBþNat Sulph-200.
p-DAB, p-dimethylaminoazobenzene; PB, phenobarbital; Nat Sulph-200, Natrum Sulphuricum-200; SE, standard error.
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In the present study, several widely accepted toxicity
markers have been used, all of which are known to have
significant role during the carcinogenesis process
(14,35–44). In brief, the significant reduction of biomar-
kers like AST, ALT, AcP, AlkP and LPO and increase of
GSH in the drug fed series speak for the reduction of
hepato-toxicity and injury (14,35). Positive modulations
of several other parameters, such as, blood glucose,
cholesterol, testosterone and estradiol were also noted
(data not shown). Similarly, there were evidences from
electron microscopic studies (both scanning, Fig. 3; and
Table 8. Showing two-way ANOVA analyses for different cytogenetical parameters
Two way ANOVA Mitotic index Chromosome Aberration Micro nucleated Erythrocytes Sperm Head Anomaly
Source of Variation df MS F MS F MS F MS F
Dues to Series 4 23.26 11.23* 289.13 39.45* 0.8247 95.82* 5.26 15.02*
Due to Days 5 11.67 5.64* 45.85 6.26* 0.03821 4.44* 1.46 4.18*
*P50.05
Table 9. Showing two-way ANOVA analyses for different enzymatic parameters
Two way ANOVA AST activity ALT activity AcP activity AlkP activity LPO activity GSH content
Source of Variation df MS F MS F MS F MS F MS F MS F
Dues to Series 4 0.0016054 17.90* 0.0002548 14.12 0.003271 13.39 0.002043 4.10 0.02558* 16.78 0.0000218 33.03
Due to Days 5 0.0009453 10.54* 0.0000997 5.52 0.006541 26.79 0.00 6.06 0.03844 25.22 0.00 7.52
*P50.05
Figure 3. Section of liver under SEM: showing features of normal
(3a-3b), p-DABþPBþAlcohol fed (3c-3d) and p-DABþPBþNat
Sulph-200 fed mice (3c-3f).
Figure 4. Liver section under TEM: showing features of normal (4a-4b).
p-DABþPBþAlcohol fed (4c-4d) and p-DABþPBþNat sulph-200
fed mice (4c-4d).
eCAM 2009;6(1) 73transmission, Fig. 4) on liver that the homeopathic
remedy played a positive role in protecting ultra-
structural integrities (data not shown). Incidentally,
reactive oxygen species (ROS) are produced by metabo-
lism of various endogenous and exogenous compounds
and are associated in the pathogenesis of different liver
diseases, such as cirrhosis and hepatocellular cancer (41–
44). In cirrhosis and hepatocellular carcinoma, the
antioxidant system is damaged severely and the GSH
level falls down, the MDA level rises and GSH-
dependent enzyme activities are enhanced in cirrhotic
and cancer tissues (43). Incidentally, positive effects of
homeopathic preparations on human prostate cancer
growth have recently been studied by Maclaughlin et al.
(45) and Jonas et al., (46) while crude extracts of some
plants have also been shown to have anti-cancerous
activities against prostate cancer cell line in human (47)
and in skin carcinogenesis (48) and leukemia and aging
(49) of mice.
In recent years, cell death in brain cancer has been
observed by some workers (50) by administering a
homeopathic drug, Ruta 6, both on in vivo and in vitro
systems. But how the micro doses of the highly diluted
homeopathic remedy could bring about such positive
changes in diverse parameters of study is not yet properly
understood. The ability of the homeopathic remedy in
bringing down cytogenetical damage along with the
positive biochemical changes can be considered as
proofs of their ability towards restoring normalcy in the
functioning of body’s important metabolic enzymes and
mechanism of repair and retrieval for genome, presum-
ably by activating/deactivating the relevant genes respon-
sible for regulation of their respective activities (51,31,32).
Conclusions
Finally, compared with Nat Sulph-30, Nat Sulph-200
appeared to show a little better efficacy in reducing the
incidence of tumors in liver, and most other common
parameters tested with both potencies, particularly at
some longer intervals of fixation. Therefore, other
researchers are encouraged to replicate the study in
mice and/or other mammalian models and see if
potentized remedies of Natrum Sulphuricum can be
recommended as a potential supportive medicine for use
in human cancer therapy as well.
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